BEVERLY, Mass.--(BUSINESS WIRE)--INVO Bioscience, Inc. (OTC BB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, announced that the $500,000 private placement / or equity securities financing that was outlined in the 8K filing dated July of 2009 has been fully subscribed. “This financing will allow INVO to bridge to long term financing in which terms are currently being negotiated as well as allow us to continue to with product launch,” said INVO Bioscience’s CEO, Kathleen Karloff.
